Results 1 to 10 of about 112,622 (301)

SOX5 inhibition overcomes PARP inhibitor resistance in BRCA-mutated breast and ovarian cancer [PDF]

Cell Death and Disease
Poly (ADP-ribose) polymerase (PARP) inhibitors are effective in cells with homologous recombination (HR) deficiency, including BRCA1/2 mutation. However, PARP inhibitors remain a therapeutic challenge in breast and ovarian cancer due to inevitably ...
Mithun Ghosh, Min Sil Kang, Nar Bahadur Katuwal, Sa Deok Hong, Seong Min Park, Seul-Gi Kim, Seung Ryeol Lee, Yong Wha Moon   +7 more
doaj   +2 more sources

Radiosensitization Effect of PARP Inhibitor Talazoparib Involves Decreasing Mitochondrial Membrane Potential and Induction of Cellular Senescence [PDF]

Current Issues in Molecular Biology
Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPis) with radiation therapy can enhance the sensitivity of cancer cells by inhibiting DNA repair pathways.
Barkha Saraswat, Ankitha Vadi Velu, Zhongming Gao, Zongxiang Zhang, Haoyang Zhu, Ying Tong, Mitsuko Masutani   +6 more
doaj   +2 more sources

PARP inhibitors [PDF]

Hereditary Cancer in Clinical Practice, 2015
بوليميرازات بولي (ADP - ريبوز)، التي يتم اختصارها باسم PARPs، هي مجموعة من البروتينات المألوفة التي تلعب دورًا مركزيًا في إصلاح الحمض النووي باستخدام مسار إصلاح استئصال القاعدة (BER). هناك حوالي 17 بروتينًا في هذه العائلة منها PARPs النووية الأولية هي PARP -1 و PARP -2 و PARP -3 و tankyrases 1 و 2 (PARP -5a و -5b).
Maheen Anwar, Hafiz Muhammad Aslam, Shahzad Anwar   +2 more
  +6 more sources

PARP inhibitor ABT-888 affects response of MDA-MB-231 cells to doxorubicin treatment, targeting Snail expression [PDF]

, 2015
To overcome cancer cells resistance to pharmacological therapy, the development of new therapeutic approaches becomes urgent. For this purpose, the use of poly(ADP-ribose) polymerase (PARP) inhibitors in combination with other cytotoxic agents could ...
CAIAFA, Paola, CALABRESE, ROBERTA, CICCARONE, FABIO, Daniela Trisciuoglio, Donatella Del Bufalo, GUASTAFIERRO, Tiziana, MARIANO, GERMANO, REALE, Anna, RICCIARDI, Maria Rosaria, TAFURI, Agostino, VALENTINI, ELISABETTA, ZAMPIERI, Michele   +11 more
core   +18 more sources

Drug-Induced Interstitial Lung Disease From PARP Inhibitors (Olaparib and Niraparib) for Ovarian Cancer

Annals of Internal Medicine: Clinical Cases, 2023
Poly (ADP-ribose) polymerase (PARP) inhibitors are approved for the treatment of several types of cancers. We report a case of an 80-year-old Japanese woman who developed drug-induced interstitial lung disease (ILD) during treatment with PARP inhibitors (
Hiroshi Sugimoto, Takanori Enomoto, Mamoru Okuno, Naoko Chayahara, Hiroki Morita, Kyosuke Nakata   +5 more
doaj   +1 more source

Evidence for Two Modes of Synergistic Induction of Apoptosis by Mapatumumab and Oxaliplatin in Combination with Hyperthermia in Human Colon Cancer Cells [PDF]

, 2013
Colorectal cancer is the third leading cause of cancer-related mortality in the world-- the main cause of death from colorectal cancer is hepatic metastases, which can be treated with isolated hepatic perfusion (IHP).
A Jemal, A Krueger, A Krueger, A Younes, AR Safa, BR Seo, C Liu, C Odoux, CH Mom, D Atallah, D Mahalingam, DB Longley, E Raymond, FA Greco, GJ Ullenhag, HJ Zeh 3rd, HR Alexander Jr., IA Mawji, IN Lavrik, J Yoo, JA Ubersax, JM Cummins, JW Yu, L Zhang, L Zhao, LR Hafström, LY Dimberg, M Irmler, M Upreti, M Vulfovich, MA Alcala Jr., MJ Lee, P Korkolopoulou, Raffaele A Calogero, S Hegewisch-Becker, S Varghese, Seog-Young Kim, SK Libutti, T Bartke, T Ruers, T Trarbach, TR Wilson, W Gao, X Song, X Song, X Song, Xinxin Song, Y Jin-Song, Y Lin, YJ Lee, YL Zhang, Yong J. Lee, Z El Fajoui   +52 more
core   +12 more sources

Combined inhibition of PARP and EZH2 for cancer treatment: Current status, opportunities, and challenges

Frontiers in Pharmacology, 2022
Tumors with BRCA1/2 mutations or homologous recombination repair defects are sensitive to PARP inhibitors through the mechanism of synthetic lethality. Several PARP inhibitors are currently approved for ovarian, breast and pancreatic cancer in clinical ...
Xi Zhang, Xiao Huo, Xiao Huo, Hongyan Guo, Lixiang Xue, Lixiang Xue   +5 more
doaj   +1 more source

PARP inhibition promotes ferroptosis via repressing SLC7A11 and synergizes with ferroptosis inducers in BRCA-proficient ovarian cancer

Redox Biology, 2021
Pharmacologic inhibition of PARP is the primary therapeutic strategy for BRCA mutant ovarian cancer. However, most of patients carry wild-type BRCA1/2 with no significant clinical benefits from PARP inhibitors, calling for the needs to further ...
Ting Hong, Guang Lei, Xue Chen, He Li, Xiaoye Zhang, Nayiyuan Wu, Yu Zhao, Yilei Zhang, Jing Wang   +8 more
doaj   +1 more source

In silico screening identifies a novel small molecule inhibitor that counteracts PARP inhibitor resistance in ovarian cancer

Scientific Reports, 2021
Poly ADP-ribose polymerase (PARP) inhibitors are promising targeted therapy for epithelial ovarian cancer (EOC) with BRCA mutations or defective homologous recombination (HR) repair. However, reversion of BRCA mutation and restoration of HR repair in EOC
Z. Ping Lin, Nour N. Al Zouabi, Mark L. Xu, Nicole E. Bowen, Terence L. Wu, Ethan S. Lavi, Pamela H. Huang, Yong-Lian Zhu, Baek Kim, Elena S. Ratner   +9 more
doaj   +1 more source

A ribosomal gene panel predicting a novel synthetic lethality in non-BRCAness tumors

Signal Transduction and Targeted Therapy, 2023
Poly (ADP-ribose) polymerase (PARP) inhibitors are one of the most exciting classes of targeted therapy agents for cancers with homologous recombination (HR) deficiency.
Chao Zhang, Qiang Guo, Lifeng Chen, Zheming Wu, Xiao-Jian Yan, Chengyang Zou, Qiuxue Zhang, Jiahong Tan, Tian Fang, Qunxian Rao, Yang Li, Shizhen Shen, Min Deng, Liewei Wang, Huanyao Gao, Jia Yu, Hu Li, Cheng Zhang, Somaira Nowsheen, Jake Kloeber, Fei Zhao, Ping Yin, Chunbo Teng, Zhongqiu Lin, Kun Song, Shuzhong Yao, Liangqing Yao, Lingying Wu, Yong Zhang, Xiaodong Cheng, Qinglei Gao, Jian Yuan, Zhenkun Lou, Jin-San Zhang   +33 more
doaj   +1 more source